LC
FULC icon

Lindbrook Capital’s Fulcrum Therapeutics FULC Stock Holding History

Lindbrook Capital’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-74
Closed -$264 – 2827
2024
Q3 		$264 Buy
+74
New +$549 ﹤0.01% 2759
2023
Q2 		– Sell
-117
Closed -$333 – 2775
2023
Q1 		$333 Buy
+117
New +$1.05K ﹤0.01% 2666
2022
Q4 		– Sell
-277
Closed -$2K – 2894
2022
Q3 		$2K Buy
277
+99
+56% +$709 ﹤0.01% 2054
2022
Q2 		$1K Sell
178
-621
-78% -$6.07K ﹤0.01% 2237
2022
Q1 		$19K Buy
+799
New +$11.3K ﹤0.01% 1023

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Lindbrook Capital's FULC Position: Q4 2024 in Review

Lindbrook Capital sold out of Fulcrum Therapeutics (FULC) in Q4 2024, closing a stake of 74 shares — an estimated $264 sold.

Lindbrook Capital first reported a position in FULC in Q1 2022 and held it in 5 quarters. The position peaked at $19K in Q1 2022. 119 funds tracked by Wall St. Rank hold FULC as of Q4 2024.

  • Lindbrook Capital reported no remaining Fulcrum Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Lindbrook Capital sold 74 Fulcrum Therapeutics shares in Q4 2024, an estimated $264.
  • Lindbrook Capital first reported a position in Fulcrum Therapeutics in Q1 2022 and held it in 5 quarters.
  • Lindbrook Capital's Fulcrum Therapeutics position peaked at $19K in Q1 2022.
  • 119 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q4 2024.

Based on Lindbrook Capital's 13F filing for Q4 2024, filed 6 Feb 2025.